Psyence Group Inc. Announces C$600,000 Private Share Offering

LOS ANGELES— Psyence Group Inc. a biotechnology firm focused on nature-derived psilocybin for mental health and palliative care, has announced a non-brokered private placement to raise up to C$600,000. The offering, detailed in a news release dated June 18, 2025, provides for up to 6 million common shares at C$0.10 each, with no finder’s fees or commissions .

The net proceeds are earmarked to support strategic initiatives, including potential acquisitions, business combinations, or other type of “Significant Transaction” under Canadian Securities Exchange rules. The company may also allocate funds to general administrative costs, working capital, and maintaining its listing status until such strategic transactions are pursued.

The offering is expected to close on or around June 25, 2025, subject to regulatory approvals and other customary conditions. The newly issued shares will carry a statutory hold period of four months and one day, which may be extended if the company undergoes a fundamental change or reverse takeover.

Psyence Group describes itself as a life science biotechnology entity specializing in natural psilocybin products aimed at alleviating psychological trauma and mental health challenges within palliative care. The firm also owns a federally licensed ISO 22000-certified psilocybin cultivation facility, emphasizing evidence-based research integration.

While the private placement offers a financial runway for future opportunities, the company’s news release cautions that execution risks remain. These include the successful closing of the offering, identification and completion of strategic transactions, and securing required regulatory or exchange approvals